[HTML] springer.comFull View

[HTML][HTML] Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study

X Pu, Y Zhou, Y Kong, B Chen, A Yang, J Li, K Li, Y Xu… - Bmc Cancer, 2023 - Springer
Background About 10% of non-small cell lung cancer (NSCLC) patients with epidermal
growth factor receptor (EGFR) mutations are harbored as uncommon mutations. This study …
被引用次数：3 相关文章
[HTML] biomedcentral.com

[HTML][HTML] Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study

X Pu, Y Zhou, Y Kong, B Chen, A Yang… - BMC …, 2023 - bmccancer.biomedcentral.com
About 10% of non-small cell lung cancer (NSCLC) patients with epidermal growth factor
receptor (EGFR) mutations are harbored as uncommon mutations. This study aimed to …

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study

X Pu, Y Zhou, Y Kong, B Chen, A Yang, J Li… - BMC …, 2023 - pubmed.ncbi.nlm.nih.gov
Background About 10% of non-small cell lung cancer (NSCLC) patients with epidermal
growth factor receptor (EGFR) mutations are harbored as uncommon mutations. This study …
[HTML] nih.gov

[HTML][HTML] Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study

X Pu, Y Zhou, Y Kong, B Chen, A Yang, J Li, K Li… - BMC Cancer, 2023 - ncbi.nlm.nih.gov
Background About 10% of non-small cell lung cancer (NSCLC) patients with epidermal
growth factor receptor (EGFR) mutations are harbored as uncommon mutations. This study …

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study.

X Pu, Y Zhou, Y Kong, B Chen, A Yang, J Li, K Li… - BMC Cancer, 2023 - europepmc.org
Background About 10% of non-small cell lung cancer (NSCLC) patients with epidermal
growth factor receptor (EGFR) mutations are harbored as uncommon mutations. This study …

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study.

X Pu, Y Zhou, Y Kong, B Chen, A Yang, J Li… - BMC …, 2023 - search.ebscohost.com
Abstract Background: About 10% of non-small cell lung cancer (NSCLC) patients with
epidermal growth factor receptor (EGFR) mutations are harbored as uncommon mutations …

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study

X Pu, Y Zhou, Y Kong, B Chen, A Yang, J Li… - BMC …, 2023 - search.proquest.com
Background About 10% of non-small cell lung cancer (NSCLC) patients with epidermal
growth factor receptor (EGFR) mutations are harbored as uncommon mutations. This study …
[PDF] biomedcentral.com

[PDF][PDF] Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study

X Pu, Y Zhou, Y Kong, B Chen, A Yang, J Li, K Li… - 2023 - bmccancer.biomedcentral.com
Background About 10% of non-small cell lung cancer (NSCLC) patients with epidermal
growth factor receptor (EGFR) mutations are harbored as uncommon mutations. This study …

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study.

X Pu, Y Zhou, Y Kong, B Chen, A Yang, J Li, K Li… - BMC Cancer, 2023 - europepmc.org
Background About 10% of non-small cell lung cancer (NSCLC) patients with epidermal
growth factor receptor (EGFR) mutations are harbored as uncommon mutations. This study …